Foundry Partners’s NeoGenomics NEO Stock Holding History

Foundry Partners’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-42,861	Closed	-$2.07M	–	415
2021 Q1	$2.07M	Sell	42,861 -32,915	-43%	-$1.71M	0.07%	272
2020 Q4	$4.08M	Sell	75,776 -376	-0.5%	-$17K	0.16%	184
2020 Q3	$2.81M	Sell	76,152 -849	-1%	-$31.6K	0.14%	201
2020 Q2	$2.38M	Buy	77,001 +8,079	+12%	+$224K	0.12%	226
2020 Q1	$1.9M	Buy	+68,922	New	+$2.06M	0.11%	223

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Foundry Partners's NEO Position: Q2 2021 in Review

Foundry Partners sold out of NeoGenomics (NEO) in Q2 2021, closing a stake of 42,861 shares — an estimated $2.07M sold.

Foundry Partners first reported a position in NEO in Q1 2020 and held it in 5 quarters. The position peaked at $4.08M in Q4 2020. 311 funds tracked by Wall St. Rank hold NEO as of Q2 2021.

Foundry Partners reported no remaining NeoGenomics position as of Q2 2021 after selling out during the quarter.
Foundry Partners sold 42,861 NeoGenomics shares in Q2 2021, an estimated $2.07M.
Foundry Partners first reported a position in NeoGenomics in Q1 2020 and held it in 5 quarters.
Foundry Partners's NeoGenomics position peaked at $4.08M in Q4 2020.
311 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2021.

Based on Foundry Partners's 13F filing for Q2 2021, filed 23 Jul 2021.